Clinical Trial Update: Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating dasatinib as first-line therapy in patients with gastrointestinal stromal tumor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED